Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$111.34M$111.34M+17.6% vs Q2 2019 Net Income-$150.82M-$150.82MN/M vs Q2 2019 EPS Diluted-$1.93-$1.93N/M vs Q2 2019 Operating Income-$138,353,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$126,772,000N/M Margins · derivedOperating margin-124.3%+166.6 pt vs Q2 2019
Net margin-135.5%+156.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end